Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)

Historical Holders from Q1 2023 to Q3 2025

Type / Class
Equity / Common Stock, $0.001 par value
Symbol
IKT on Nasdaq
Shares outstanding
120,494,078
Price per share
$1.62
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
54,964,771
Holdings value
$89,043,214
% of all portfolios
0%
Share change
+446,216
Value change
+$712,913
Average buys %
+0%
Average sells %
-0%
Number of holders
53
Price from insider filings
$1.45
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Sands Capital Life Sciences Pulse Fund II, L.P. 15% $20,257,500 10,950,000 Sands Capital Life Sciences Pulse Fund II, L.P. 30 Jun 2025
ADAR1 Capital Management, LLC 9.9% -0.9% $14,314,734 +$1,375,379 7,737,694 +11% ADAR1 Capital Management GP, LLC 30 Jun 2025
Fairmount Funds Management LLC 9.9% $15,861,980 7,018,575 Fairmount Funds Management LLC 31 Dec 2024
Trails Edge Capital Partners, LP 5.1% $9,525,057 6,145,198 Trails Edge Capital Partners, LP 23 Dec 2025
Nantahala Capital Management, LLC 7.5% $11,974,890 5,298,624 Nantahala Capital Management, LLC 31 Dec 2024
ARMISTICE CAPITAL, LLC 5% $7,975,554 3,529,006 Armistice Capital, LLC 31 Dec 2024
As of 30 Sep 2025, Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) has 53 institutional shareholders filing 13F forms. They hold 54,964,771 shares of 120,494,078 outstanding shares (46%) .

Top 25 institutional shareholders own 45% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Sands Capital Alternatives, LLC 9.1% 10,950,000 0% 3.9% $17,739,000
Soleus Capital Management, L.P. 5.2% 6,325,000 0% 0.55% $10,246,500
Fairmount Funds Management LLC 5.1% 6,125,000 0% 0.89% $9,922,500
PERCEPTIVE ADVISORS LLC 4.5% 5,421,568 -0.2% 0.26% $8,782,940
Commodore Capital LP 4.5% 5,397,488 0% 0.43% $8,743,931
ADAR1 Capital Management, LLC 4.4% 5,247,603 +2.5% 0.85% $8,501,117
VANGUARD GROUP INC 2.7% 3,273,339 +1.5% 0% $5,302,809
BlackRock, Inc. 2.6% 3,075,186 +13% 0% $4,981,802
Blackstone Inc. 2.2% 2,638,276 0% 0.02% $4,274,007
Nantahala Capital Management, LLC 1.8% 2,190,000 0% 0.22% $3,547,800
GEODE CAPITAL MANAGEMENT, LLC 0.92% 1,112,574 +4.3% 0% $1,802,466
Stonepine Capital Management, LLC 0.61% 735,019 +0.17% 0.97% $1,190,731
STATE STREET CORP 0.42% 507,749 +28% 0% $822,553
NORTHERN TRUST CORP 0.31% 374,336 -4.7% 0% $606,424
BLAIR WILLIAM & CO/IL 0.13% 152,953 -2.5% 0% $247,784
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.13% 152,298 0% 0% $246,723
Bank of New York Mellon Corp 0.12% 138,667 +4.7% 0% $224,641
UBS Group AG 0.11% 136,280 +252% 0% $220,773
FMR LLC 0.09% 105,770 -27% 0% $171,347
BARCLAYS PLC 0.07% 85,578 -22% 0% $138,636
DEUTSCHE BANK AG\ 0.07% 80,496 0% $130,404
Nuveen, LLC 0.07% 78,659 0% 0% $127,428
CITADEL ADVISORS LLC 0.06% 71,670 0% $116,105
RHUMBLINE ADVISERS 0.05% 57,551 -1.7% 0% $93,226
MORGAN STANLEY 0.05% 56,019 -44% 0% $90,753

Institutional Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 54,964,771 $89,043,214 +$712,913 $1.62 53
2025 Q2 54,512,097 $106,299,597 +$5,482,917 $1.95 48
2025 Q1 51,462,756 $112,702,942 +$3,027,389 $2.19 47
2024 Q4 50,059,308 $162,691,896 +$161,164,562 $3.25 31
2024 Q3 860,232 $1,118,330 +$30,199 $1.30 11
2024 Q2 836,496 $1,021,038 +$723,392 $1.21 12
2024 Q1 205,558 $443,782 -$62,190 $2.16 12
2023 Q4 235,004 $298,925 -$271,105 $1.27 11
2023 Q3 429,662 $597,627 -$496,803 $1.39 13
2023 Q2 747,138 $2,693,647 +$2,394,678 $3.61 14
2023 Q1 82,817 $54,460 +$54,460 $0.6576 1